198 related articles for article (PubMed ID: 27885740)
1. ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.
Kikuchi A; Suzuki T; Nakazawa T; Iizuka M; Nakayama A; Ozawa T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
Cancer Sci; 2017 Feb; 108(2):236-242. PubMed ID: 27885740
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
[TBL] [Abstract][Full Text] [Related]
3. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
Miyake M; Ishii M; Koyama N; Kawashima K; Kodama T; Anai S; Fujimoto K; Hirao Y; Sugano K
J Pharmacol Exp Ther; 2010 Mar; 332(3):795-802. PubMed ID: 19955487
[TBL] [Abstract][Full Text] [Related]
4. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
5. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies.
Yamamoto N; Ryoo BY; Keam B; Kudo M; Lin CC; Kunieda F; Ball HA; Moran D; Komatsu K; Takeda K; Fukuda M; Furuse J; Morita S; Doi T
Invest New Drugs; 2020 Apr; 38(2):445-456. PubMed ID: 31041575
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations.
Lima NC; Atkinson E; Bunney TD; Katan M; Huang PH
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370101
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
[TBL] [Abstract][Full Text] [Related]
9. ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma.
Futami T; Okada H; Kihara R; Kawase T; Nakayama A; Suzuki T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
Mol Cancer Ther; 2017 Jan; 16(1):68-75. PubMed ID: 27837028
[TBL] [Abstract][Full Text] [Related]
10. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.
Datta J; Damodaran S; Parks H; Ocrainiciuc C; Miya J; Yu L; Gardner EP; Samorodnitsky E; Wing MR; Bhatt D; Hays J; Reeser JW; Roychowdhury S
Mol Cancer Ther; 2017 Apr; 16(4):614-624. PubMed ID: 28255027
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor (
Al-Obaidy KI; Cheng L
J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
Milowsky MI; Dittrich C; Durán I; Jagdev S; Millard FE; Sweeney CJ; Bajorin D; Cerbone L; Quinn DI; Stadler WM; Rosenberg JE; Lochheed M; Sen P; Squires M; Shi M; Sternberg CN
Eur J Cancer; 2014 Dec; 50(18):3145-52. PubMed ID: 25457633
[TBL] [Abstract][Full Text] [Related]
13. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells.
Wang J; Mikse O; Liao RG; Li Y; Tan L; Janne PA; Gray NS; Wong KK; Hammerman PS
Oncogene; 2015 Apr; 34(17):2167-77. PubMed ID: 24909170
[TBL] [Abstract][Full Text] [Related]
14. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
[TBL] [Abstract][Full Text] [Related]
16. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
[TBL] [Abstract][Full Text] [Related]
17. The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
Balasooriya ER; Wu Q; Ellis H; Zhen Y; Norden BL; Corcoran RB; Mohan A; Martin E; Franovic A; Tyhonas J; Lardy M; Grandinetti KB; Pelham R; Soroceanu L; Silveira VS; Bardeesy N
Clin Cancer Res; 2024 May; 30(10):2181-2192. PubMed ID: 38437671
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with
Pal SK; Rosenberg JE; Hoffman-Censits JH; Berger R; Quinn DI; Galsky MD; Wolf J; Dittrich C; Keam B; Delord JP; Schellens JHM; Gravis G; Medioni J; Maroto P; Sriuranpong V; Charoentum C; Burris HA; Grünwald V; Petrylak D; Vaishampayan U; Gez E; De Giorgi U; Lee JL; Voortman J; Gupta S; Sharma S; Mortazavi A; Vaughn DJ; Isaacs R; Parker K; Chen X; Yu K; Porter D; Graus Porta D; Bajorin DF
Cancer Discov; 2018 Jul; 8(7):812-821. PubMed ID: 29848605
[TBL] [Abstract][Full Text] [Related]
19. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
[TBL] [Abstract][Full Text] [Related]
20. Complexity of FGFR signalling in metastatic urothelial cancer.
Rodriguez-Vida A; Saggese M; Hughes S; Rudman S; Chowdhury S; Smith NR; Lawrence P; Rooney C; Dougherty B; Landers D; Kilgour E; Arkenau HT
J Hematol Oncol; 2015 Oct; 8():119. PubMed ID: 26497743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
